| Description | Cilazapril is an angiotensin-converting enzyme inhibitor. It has been researched for mild to moderate essential hypertension. |
| Synonyms | Ro-34-2848, Ro 34-2848, Cilazapril (anhydrous), Ro34-2848, 西拉普利 |
| molecular weight | 417.5 |
| Molecular formula | C22H31N3O5 |
| CAS | 88768-40-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Soluble |
| References | 1. Stanisz BJ, Paszun SK, Zalewska A. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6. PubMed PMID: 25272892. 2. Paszun SK, Stanisz BJ, Gradowska A. Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Acta Pol Pharm. 2013 Nov-Dec;70(6):1079-85. PubMed PMID: 24383331. 3. Narayanam M, Sahu A, Singh S. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. J Pharm Biomed Anal. 2015;111:190-203. doi: 10.1016/j.jpba.2015.03.038. Epub 2015 Apr 3. PubMed PMID: 25890215. 4. Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL. Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. J AOAC Int. 2011 May-Jun;94(3):758-64. PubMed PMID: 21797003. |